We are harnessing powerful human biology to radically reshape the treatment of some of today’s toughest diseases.Discover More
We aspire to operate one of the most productive R&D engines in the biopharma industry.
Our broad, diverse pipeline of novel, first-in-class medicines spans multiple therapeutic areas and diseases. Every program focuses on a large market indication with high unmet needs and a common goal: delivering outsized impact for patients.
NGM Bio Announces Preliminary Results from Phase 1b Study of NGM313 in Obese, Insulin Resistant Subjects with Nonalcoholic Fatty Liver Disease (NAFLD)
NGM Bio Announces New Histology Data from Phase 2 Trial of NGM282 in Patients with NASH
NGM Bio Announces Multiple Presentations at AASLD’s The Liver Meeting®, Including New NASH Histology Data from the Phase 2 Trial of NGM282 and Topline Phase 1b Data for NGM313
NGM282 for NASH
Significantly improving liver steatosis, inflammation, and fibrosis.
Our lead product, NGM282, is a first-in-class, non-tumorigenic, engineered variant of the human hormone FGF19 that has demonstrated a rapid regression of liver fibrosis and improvement in liver function by targeting multiple pathogenic pathways of NASH.MORE ABOUT NGM282
Our People Are Our Platform.
What makes NGM tick? Really smart team members who love working together to pursue great science and share a common drive to deliver a huge impact for patients. We have no hierarchies. We collaborate intensively, embrace risk freely and always swing for the fence.Join Us